key: cord-0704589-xhsxwuww authors: Rubio‐Rivas, Manuel; Forero, Carlos G.; Mora‐Luján, José María; Montero, Abelardo; Formiga, Francesc; Homs, Narcís A.; Albà‐Albalate, Joan; Sánchez, Laura; Rello, Jordi; Corbella, Xavier title: Beneficial and harmful outcomes of tocilizumab in severe COVID‐19: A systematic review and meta‐analysis date: 2021-10-01 journal: Pharmacotherapy DOI: 10.1002/phar.2627 sha: 5562ff2a3b72fcf5f0bde31bb0e6ab345ad3838e doc_id: 704589 cord_uid: xhsxwuww INTRODUCTION: The results of studies of tocilizumab (TCZ) in COVID‐19 are contradictory. Our study aims to update medical evidence from controlled observational studies and randomized clinical trials (RCTs) on the use of TCZ in hospitalized patients with COVID‐19. METHODS: We searched the following databases from January 1, 2020 to April 13, 2021 (date of the last search): MEDLINE database through the PubMed search engine and Scopus, using the terms (“COVID‐19" [Supplementary Concept]) AND "tocilizumab" [Supplementary Concept]). RESULTS: Sixty four studies were included in the present study: 54 were controlled observational studies (50 retrospective and 4 prospective) and 10 were RCTs. The overall results provided data from 20,616 hospitalized patients with COVID‐19: 7668 patients received TCZ in addition to standard of care (SOC) (including 1915 patients admitted to intensive care units (ICU) with reported mortality) and 12,948 patients only receiving SOC (including 4410 patients admitted to the ICU with reported mortality). After applying the random‐effects model, the hospital‐wide (including ICU) pooled mortality odds ratio (OR) of patients with COVID‐19 treated with TCZ was 0.73 (95% confidence interval (CI) = 0.56–0.93). The pooled hospital‐wide mortality OR was 1.25 (95% CI = 0.74–2.18) in patients admitted at conventional wards versus 0.66 (95% CI = 0.59–0.76) in patients admitted to the ICU. The pooled OR of hospital‐wide mortality (including ICU) of COVID‐19 patients treated with TCZ plus corticosteroids (CS) was 0.67 (95% CI = 0.54–0.84). The pooled in‐hospital mortality OR was 0.71 (95% CI = 0.35–1.42) when TCZ was early administered (≤10 days from symptom onset) versus 0.83 (95% CI 0.48–1.45) for late administration (>10 days from symptom onset). The meta‐analysis did not find significantly higher risk for secondary infections in COVID‐19 patients treated with TCZ. CONCLUSIONS: TCZ prevented mortality in patients hospitalized for COVID‐19. This benefit was seen to a greater extent in patients receiving concomitant CS and when TCZ administration occurred within the first 10 days after symptom onset. After more than 1 year into the COVID-19 pandemic, only a few therapies have withstood the inexorable push of scientific evidence. Basically, treatments aimed at blocking the cytokine storm that accompanies COVID-19 persist, including corticosteroids (CS) and tocilizumab (TCZ). Tocilizumab is a humanized monoclonal antibody of the IgG1 subclass that inhibits signaling of interleukin 6 (IL-6). Although in the case of CS, there is more unanimity in favor of their benefits, 2 published evidence of TCZ treatment in patients with COVID-19 has been still controversial, lengthening the debate on its use to this day. Interestingly, there are almost a hundred uncontrolled 3-39 and controlled observational studies published to date, in which TCZ generally improved survival in hospitalized patients with COVID-19. On the contrary, randomized clinical trials (RCTs) evaluating the efficacy of TCZ in COVID- 19 have been reported scarcely, with mixed results. [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] A few systematic reviews and meta-analyses (SRMAs) of TCZ in COVID- 19 have been published, also with changing results as new studies are published. [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] Our study aims to update published evidence from controlled observational studies and trials on the effect of TCZ use in different subgroups of patients with COVID-19 requiring hospitalization. This report describes the results of a systematic review and metaanalysis following the guidance of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. 122 The protocol was published in the National Institute for Health Research international register of systematic reviews (PROSPERO) (registration number CRD42020204934). A clinical question under the Population-Intervention-Comparison-Outcome (PICO) framework format was created (Supporting Information S1). The search strategy was developed by three investigators (M.R-R., C.G.F., and X.C.), which was revised and approved by the other inves- Full-text observational studies and trials in any language reporting beneficial or harmful outcomes on the use of TCZ in adults hospi- Publications were included if they met all of the following criteria: (1) the study reported data on adults ≥18 years with COVID-19, diagnosed by polymerase chain reaction (PCR), and admitted hospital-wide or in intensive care units (ICUs); (2) the study design was an observational or experimental investigation providing original data on TCZ use in COVID-19, either intravenous or subcutaneous; and (3) the study data collection finished after January 1, 2020. Studies reported as "case-control studies," in which subjects from the control group also presented COVID-19, just as those from the TCZ group, were also included in the present review. Studies focusing on a sole subgroup of patients (e.g., renal transplant recipients) were excluded. Furthermore, studies with overlapping data (e.g., the same series reported in different studies) were rejected to avoid bias due to data overexpression. In such cases, the latest and/ or largest study was selected. For this purpose, a careful revision was performed of patients' origins included in studies from the same country not to include patients from the same hospital. When patients came from the same hospital, the larger study was chosen. coronavirus, COVID-19, meta-analysis, SARS-CoV-2, systematic review, tocilizumab The search was completed by the bibliography review of every article selected for full-text examination. Categorical variables were described as sample size-weighted absolute numbers and percentages. When the number of events and the sample size were small (and followed a Poisson distribution), confidence intervals were estimated using Wilson's method. 125 , 126 We carried out a meta-analysis of the pooled mortality odds ratio (OR) of mortality in TCZ-treated patients versus non-TCZ-treated patients (OR of 1). We conducted random-effects meta-analysis assuming that there is an underlying effect for each study which varies randomly across studies, with the resulting overall effect an average of these. 127 Studies with 0 events in one arm were not included in the metaanalysis as recommended, using restricted maximum likelihood (REML), stratified by study design. 128 A total of 3420 articles were identified in our search. Of these, 150 qualified for full-text review following title and abstract screening, of which 64 studies 40-96,99,100,103--107 were included in the analysis. The PRISMA flow diagram is detailed in Figure 1 . Of After applying the random-effects model, hospital-wide (includ- Sensitivity analysis excluding these studies showed an 8% significant increase in the effect size and 5% reduction in heterogeneity (Supporting After applying the random-effects model, the pooled risk of the ICU admission OR for COVID-19 patients in whom TCZ was administered in the conventional ward was 3.70 (95% CI = 1.25-10.80). The median follow-up of the overall cohort was 28 [range days. After applying the random-effects model, the pooled risk of secondary infections OR for COVID-19 patients treated with TCZ was 1.04 (95% CI = 0.72-1.52) (Supporting Information S10). which was more representative of an outpatient population not requiring immunosuppressive treatments, rather than that of patients who met hospitalization criteria used worldwide. In an ideal scenario, it would be necessary to perform subanalyses to analyze the true efficacy and safety of TCZ at different stages of the disease and in different settings. For example, the potential beneficial or harmful effect of TCZ may not be the same in studies performed in inflamed versus noninflamed patients, in patients receiving TCZ with corticosteroids compared with TCZ alone, in patients treated in conventional wards compared with ICUs, in developed versus developing countries, or at the first wave of the pandemic in the spring of 2020 compared with the current days more than 1 year after the start of the COVID-19 pandemic. In general, the patients included in the different studies included in this SRMA received a single dose of TCZ. However, some patients received two doses and very rarely three doses. It is not possible from the data we have to analyze whether the number of doses influences in-hospital mortality. Furthermore, it should be taken into account that those patients who received more than one dose were patients who were somehow interpreted by their physicians to be more severely ill. Thus, it is possible that paradoxically, we found that the more doses of TCZ, the greater the mortality risk. The low use of remdesivir in the included studies is striking. Possibly, this is due to the poor availability of the drug at many times during the pandemic and in certain countries. At least it helps us in the present SRMA as the use of remdesivir does not add a confounding factor to the results. From the subanalysis performed taking into account the day of TCZ administration, it is intuited that early administration before Day 10 of symptoms could be beneficial. It is only an approximation based on the mean of the day of TCZ administration in the study and, therefore, includes patients in a wide range on the day of administration. On the other hand, it has been said that the escalation of inflammation occurs in the second week from the onset of symptoms. This is more of a philosophical model than a real one based on scientific evidence. The reality is that there are patients who become inflamed in the second week, whereas others present very early inflammation. The higher OR found in our study of admission to the ICU in patients with COVID-19 who received TCZ should not lead us to think that by receiving this drug, more patients will require admission to the ICU. These data clearly indicate that patients with greater disease severity have more easily received TCZ. For this reason, in an RCT, it is so important to define the disease severity of the patient when receiving TCZ or the corresponding SOC. We believe that this disease severity should be evaluated not only with the respiratory status but also with the degree of analytical inflammation of the patient. In the present SRMA, we found a greater benefit with the use of TCZ versus SOC in ICU patients compared with ward patients. The more inflamed the patients are, the more these differences will be seen. Patients admitted to the ICU for COVID-19 generally have a high degree of inflammation, and therefore, the beneficial effect of TCZ becomes more evident. However, in conventional ward patients who are often not inflamed or have mild degrees of inflammation, if these inflamed ward patients are not well-selected, the possible beneficial effect of TCZ is diluted. Regarding the safety of TCZ, we can say that from the data analyzed in our SRMA, it seems to be a safe drug in terms of the rate of secondary infections. The current meta-analysis did not find a significantly higher risk for secondary infections in patients with COVID-19 treated with TCZ. As TCZ has been administered to more severe patients with COVID-19, many of them in the ICU or requiring ICU admission during the follow-up, a higher incidence of infections is to be expected in this subpopulation. The causes are known and multifactorial, especially related to a greater number of invasive procedures, including MV, in more severely ill patients. In this SRMA, we tried to approximate these subanalyses in accordance with the data provided in the included studies. Despite limitations, we believe that the scientific community is getting closer to the truth regarding the effect of TCZ use in COVID-19 and will get even closer in the future as patient selection in these studies improves, particularly if patient selection is increasingly based on inflammatory severity criteria. 132 The sooner we define this subpopulation of patients who meet severe inflammatory criteria, the sooner we will probably see the real effects of TCZ therapy in We thank CERCA Programme/Generalitat de Catalunya for institutional support. Jordi Rello has received consultancy honoraria from Roche. All other authors declare no conflicts of interest. Manuel Rubio-Rivas https://orcid.org/0000-0002-9548-1374 Tocilizumab for the treatment of noncritical COVID-19 pneumonia: an overview of the rationale and clinical evidence to date Dexamethasone in hospitalized patients with Covid-19 Effective treatment of severe COVID-19 patients with tocilizumab Tocilizumab treatment in COVID-19: a single center experience Early use of tocilizumab in the prevention of adult respiratory failure in SARS -CoV -2 infections and the utilization of interleukin -6 levels in the management Higher levels of IL-6 early after tocilizumab distinguish survivors from non-survivors in COVID-19 pneumonia: a possible indication for deeper targeting IL-6 Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Tocilizumab for the treatment of severe COVID-19 Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19 Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients Compassionate use of tocilizumab for treatment of SARS-CoV-2 pneumonia Tocilizumab challenge: a series of cytokine storm therapy experiences in hospitalized COVID-19 pneumonia patients Feasibility of tocilizumab in ICU patients with COVID-19 Early tocilizumab treatment could improve survival among COVID-19 patients Methylprednisolone added to tocilizumab reduces mortality in SARS-CoV-2 pneumonia: an observational study Tocilizumab in patients with severe COVID-19: A single-center observational analysis Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19) Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration Tocilizumab as a therapeutic agent for critically ill patients infected with SARS-CoV-2 Compassionate use of tocilizumab in severe SARS-CoV-2 pneumonia Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: a retrospective cohort study Temporal clinical and laboratory response to interleukin-6 receptor blockade with Tocilizumab in 89 hospitalized patients with COVID-19 pneumonia Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness Clinical outcomes following tocilizumab administration in mechanically ventilated coronavirus disease 2019 patients The effect of tocilizumab on cytokine release syndrome in COVID-19 patients Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19 Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: a retrospective case series Outcome of COVID-19 patients with use of Tocilizumab: a single center experience Tocilizumab for severe COVID-19 related illness -a community academic medical center experience Treatment with tocilizumab for patients with Covid-19 infections: a case-series study Tocilizumab therapy for COVID-19: a comparison of subcutaneous and intravenous therapies Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: covizumab-6 observational cohort Appropriate use of tocilizumab in COVID-19 infection Preemptive interleukin-6 blockade in patients with COVID-19 Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study Tocilizumab in patients with severe COVID-19: a retrospective cohort study Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-center retrospective cohort study COVID IRCCS San Matteo Pavia Task Force. Tocilizumab for treatment of severe COVID-19 patients: preliminary results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms Tocilizumab treatment for cytokine release syndrome in hospitalized COVID-19 patients: survival and clinical outcomes The association of interleukin-6 value, interleukin inhibitors and outcomes of patients with COVID-19 in New York City Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: a comparative analysis Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study IL6 inhibition in critically ill COVID-19 patients is associated with increased secondaryInfections Impact of tocilizumab administration on mortality in severe COVID-19 Tocilizumab for treatment of patients with severe COVID19: a retrospective cohort study Use of the IL-6R antagonist tocilizumab in hospitalized COVID-19 patients Outcomes in patients with severe COVID-19 disease treated with tocilizumab -a casecontrolled study Tocilizumab for severe worsening COVID-19 pneumonia: a propensity score analysis Effect of tocilizumab in hospitalized patients with severe COVID-19 pneumonia: a casecontrol cohort study Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: a retrospective case-control survival analysis of 128 patients Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study Observational study on off-label use of tocilizumab in patients with severe COVID-19 IL-6 serum levels predict severity and response to Tocilizumab in COVID-19: an observational study Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: a retrospective cohort study Clinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients Neither earlier nor late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort study Efficacy of hydroxychloroquine and tocilizumab in patients with COVID-19: single-center retrospective chart review Lack of tocilizumab effect on mortality in COVID19 patients Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19 Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: a prospective cohort study Tocilizumab improves survival in patients with persistent hypoxia in severe COVID-19 pneumonia Experience of using tocilizumab for treatment in Indonesian patients with severe COVID-19 Repurposed tocilizumab in patients with severe COVID-19 Combination of tocilizumab and steroids to improve mortality in patients with severe COVID-19 infection: a Spanish, Multicenter Cohort Study Tocilizumab in the treatment of critical COVID-19 pneumonia: a retrospective cohort study of mechanically ventilated patients Anti-IL6 treatment of serious COVID-19 disease: a monocentric retrospective experience Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: Single center cohort study of 685 patients Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study Tocilizumab-an option for patients with COVID-19 associated cytokine release syndrome: A single center experience, a retrospective study-original article Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai Tocilizumab treatment in critically ill patients with COVID-19: a retrospective observational study Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: a singlecenter retrospective study What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-an observational study Tocilizumab in hospitalized patients with COVID-19: clinical outcomes, inflammatory marker kinetics, and safety A propensity-matched cohort study of tocilizumab in patients with coronavirus disease 2019 Late onset infectious complications and safety of tocilizumab in the management of COVID-19 Tocilizumab for treatment of mechanically ventilated patients with COVID-19 Tocilizumab and steroid treatment in patients with COVID-19 pneumonia Tocilizumab use in COVID-19-associated pneumonia Tocilizumab use in COVID-19 cytokine-release syndrome: retrospective study of two centers Efficacy of tocilizumab in patients hospitalized with Covid-19 Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia. A randomized clinical trial Subcutaneous tocilizumab in adults with severe and critical COVID-19: a prospective open-label uncontrolled multicenter trial Promising effects of tocilizumab in COVID-19: a non-controlled, prospective clinical trial Tocilizumab in patients hospitalized with covid-19 pneumonia Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial Tocilizumab in COVID-19 interstitial pneumonia Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial Interleukin-6 receptor antagonists in critically ill patients with covid-19 Tocilizumab in hospitalized patients with severe covid-19 pneumonia Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Use of tocilizumab in COVID-19: a systematic review and meta-analysis of current evidence Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis Tocilizumab for severe COVID-19: a systematic review and meta-analysis Tocilizumab for treating COVID-19: a systemic review and meta-analysis of retrospective studies Efficacy of tocilizumab in COVID-19: a systematic review and meta-analysis Addition of tocilizumab to the standard of care reduces mortality in severe COVID-19: a systematic review and meta-analysis Decreased mortality in COVID-19 patients treated with Tocilizumab: a rapid systematic review and meta-analysis of observational studies Efficacy and safety of tocilizumab for coronavirus disease 2019 (covid-19) patients: a systematic review and meta-analysis Systematic review and metaanalysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19 The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials The effect of tocilizumab on COVID-19 patient mortality: a systematic review and meta-analysis of randomized controlled trials Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis Efficacy and safety of Tocilizumab in severe and critical COVID-19: a systematic review and meta-analysis IL-6 inhibition in the treatment of COVID-19: a meta-analysis and meta-regression The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in metaanalysis Probable inference, the law of succession, and statistical inference Fiducial limits for the poisson distribution Statistical Q14 Methods in Epidemiology Methods to estimate the between-study variance and its uncertainty in meta-analysis Bias in meta-analysis detected by a simple, graphical test Comparison of two methods to detect publication bias in meta-analysis Exploring heterogeneity in meta-analysis: Is the L'Abbé plot useful? Risk categories in COVID-19 based on degrees of inflammation: data on more than 17,000 patients from the Spanish SEMI-COVID-19 Registry Additional supporting information may be found in the online version of the article at the publisher's website.